Zhou A - Search Results

1

Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.

Henry DH, Glaspy J, Harrup R, Mittelman M, Zhou A, Carraway HE, Bradley C, Saha G, Modelska K, Bartels P, Leong R, Yu KP. Henry DH, et al. Among authors: zhou a. Am J Hematol. 2022 Feb 1;97(2):174-184. doi: 10.1002/ajh.26397. Epub 2021 Nov 9. Am J Hematol. 2022. PMID: 34724251 Free article. Clinical Trial.

2

A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis.

Kong T, Gaudin N, Gordon K, Cox MJ, Zhou AW, Oh ST. Kong T, et al. Ther Adv Hematol. 2024 Mar 13;15:20406207241237607. doi: 10.1177/20406207241237607. eCollection 2024. Ther Adv Hematol. 2024. PMID: 38481947 Free PMC article.

3

Outcomes of platelet transfusion in patients with thrombotic thrombocytopenic purpura: a retrospective case series study.

Zhou A, Mehta RS, Smith RE. Zhou A, et al. Ann Hematol. 2015 Mar;94(3):467-72. doi: 10.1007/s00277-014-2223-9. Epub 2014 Oct 7. Ann Hematol. 2015. PMID: 25288377

4

Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib.

Zhou A, Kong T, Fowles JS, Jung CL, Allen MJ, Fisher DAC, Fulbright M, Nemeth E, Ganz T, Oh ST. Zhou A, et al. Br J Haematol. 2022 May;197(4):e49-e52. doi: 10.1111/bjh.18044. Epub 2022 Feb 6. Br J Haematol. 2022. PMID: 35128632 No abstract available.

5

Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Fisher DAC, Fowles JS, Zhou A, Oh ST. Fisher DAC, et al. Among authors: zhou a. Front Immunol. 2021 Jun 1;12:683401. doi: 10.3389/fimmu.2021.683401. eCollection 2021. Front Immunol. 2021. PMID: 34140953 Free PMC article. Review.

6

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST. Zhou A, et al. Blood Cancer J. 2015 Oct 2;5(10):e351. doi: 10.1038/bcj.2015.77. Blood Cancer J. 2015. PMID: 26430722 Free PMC article. No abstract available.

7

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor.

Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski S, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Grossman BJ, Westervelt P, DiPersio JF, Uy GL. Crees ZD, et al. Among authors: zhou a. Blood Adv. 2023 Sep 26;7(18):5210-5214. doi: 10.1182/bloodadvances.2023010407. Blood Adv. 2023. PMID: 37327120 Free PMC article. No abstract available.

8

Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.

How J, Zhou A, Oh ST. How J, et al. Among authors: zhou a. Ther Adv Hematol. 2017 Mar;8(3):107-118. doi: 10.1177/2040620716680333. Epub 2016 Dec 8. Ther Adv Hematol. 2017. PMID: 28246554 Free PMC article. Review.

9

Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.

Zhou AW, Knoche EM, Engle EK, Ban-Hoefen M, Kaiwar C, Oh ST. Zhou AW, et al. N Engl J Med. 2016 Aug 4;375(5):494-6. doi: 10.1056/NEJMc1600337. N Engl J Med. 2016. PMID: 27518686 Free PMC article. No abstract available.

10

Induced CD8α identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation.

Cubitt CC, Wong P, Dorando HK, Foltz JA, Tran J, Marsala L, Marin ND, Foster M, Schappe T, Fatima H, Becker-Hapak M, Zhou AY, Hwang K, Jacobs MT, Russler-Germain DA, Mace EM, Berrien-Elliott MM, Payton JE, Fehniger TA. Cubitt CC, et al. Among authors: zhou ay. J Clin Invest. 2024 May 28:e173602. doi: 10.1172/JCI173602. Online ahead of print. J Clin Invest. 2024. PMID: 38805302 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,243 results

Search Page